AI could help choose the right chemo for pancreatic cancer
NCT ID NCT06320717
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This study collects blood and tumor samples from 100 people with pancreatic cancer who are about to receive standard chemotherapy. Researchers will use an artificial intelligence tool to look for biomarkers that might predict which treatment—FOLFIRINOX or Gemcitabine+Nab-paclitaxel—works best for each patient. The goal is to make it easier for future patients to get the right treatment from the start.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Good Samaritan University Hospital
RECRUITINGWest Islip, New York, 11795, United States
Contact Phone: •••-•••-••••
Contact
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.